Global Human Microbiome Market 2024

Global Human Microbiome Market 2024

The human microbiome is a complex and dynamic ecosystem of microorganisms that plays a critical role in human health and disease. Understanding the composition, function, and factors influencing the microbiome opens up new opportunities for the development of microbiome-based interventions and personalized medicine approaches aimed at promoting health and treating disease.

According to the latest estimates, the global human microbiome market is set to achieve an incremental growth of USD 1,342.3 million, accelerating at a CAGR of almost 18.6% during the forecast period 2024-2030. The market for human microbiome is characterized by several key segments, with the therapeutics segment holding a significant share due to ongoing research aimed at developing more therapeutic applications. Within this segment, the gastrointestinal disorders category is prominent, driven by the increasing incidence of gastrointestinal diseases and a corresponding rise in product launches. Geographically, North America leads the market, attributed to a higher prevalence of lifestyle-related disorders in the region and the presence of established industry players.

The market's growth is driven by several factors. Firstly, there's a notable increase in lifestyle-related diseases globally, including conditions like diabetes, asthma, and cancer. This trend necessitates advanced therapeutics and diagnostic solutions, leading to a demand surge for microbiome-based products aimed at addressing these prevalent health concerns. Additionally, the growing geriatric population is contributing significantly to the market's expansion. Aging is a primary risk factor for chronic diseases like diabetes and cancer, hence the rising elderly demographic is expected to drive the adoption of human microbiome-based products as supplements, further fueling market growth.

This comprehensive industry report provides market estimates and forecasts, accompanied by a detailed examination of the product, application, disease, and region aspects. It delivers a quantitative analysis of the market, empowering stakeholders to leverage existing market opportunities. Furthermore, the report identifies key segments for potential opportunities and strategies, drawing insights from market trends and the approaches of leading competitors.

The global human microbiome market has been extensively analyzed by categorizing it according to various sub-segments in order to provide accurate forecasts of industry size and assess trends within specific areas.

The global market for human microbiome can be segmented by product: probiotics, prebiotics, symbiotics, others. The probiotics segment held the largest share of the global human microbiome market in 2023, representing more than 59.9% of the total market.

Human microbiome market is further segmented by application: therapeutics, diagnostics. Globally, the therapeutics segment made up the largest share of the human microbiome market.

Based on disease, the human microbiome market is segmented into: autoimmune disorders, cancers, central nervous system disorders, diabetes, gastrointestinal disorders, obesity, others. The gastrointestinal disorders segment was the largest contributor to the global human microbiome market in 2023, representing more than 60.3% of the total market.

On the basis of region, the human microbiome market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global human microbiome market, representing more than 61.2% of the total market.

The report also provides a detailed analysis of several leading human microbiome market vendors that include AOBiome Therapeutics, Inc., Assembly Biosciences, Inc., Axial Therapeutics, Inc., Caelus Pharmaceuticals B.V. (Caelus Health), Chr. Hansen Inc., DayTwo Ltd., Enterome S.A., Exeliom Biosciences SAS, Finch Therapeutics Group, Inc., MaaT Pharma SA, MatriSys Bioscience, Inc., Microba Life Sciences Ltd., Osel Inc., Quantbiome, Inc. (dba Ombre), Rebiotix, Inc., Seres Therapeutics, Inc., Synlogic Inc, Vedanta Biosciences, Inc., Viome Life Sciences, Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Why Choose This Report

Gain a reliable outlook of the global human microbiome market forecasts from 2024 to 2030 across scenarios.

Identify growth segments for investment.

Stay ahead of competitors through company profiles and market data.

The market estimate for ease of analysis across scenarios in Excel format.

Strategy consulting and research support for three months.

Print authentication provided for the single-user license.

Market Segments Covered in Global Human Microbiome Industry Analysis:

i.) Product

• Probiotics
• Prebiotics
• Symbiotics
• Others

ii.) Application

• Therapeutics
• Diagnostics

iii.) Disease

• Autoimmune disorders
• Cancers
• Central nervous system disorders
• Diabetes
• Gastrointestinal disorders
• Obesity
• Others

iv.) Region

• North America
• Europe
• Asia-Pacific
• MEA (Middle East and Africa)
• Latin America